Blood- and bone marrow-based efficient growth factors extraction system demonstrates substantial equivalence and high cell viability SEOUL, South Korea, April 10, 2026 /PRNewswire/ -- Miracell, a leading stem cell technology company, announced that it has obtained U.S. FDA 510(k) clearance for its stem cell extraction system, SMART M-CELL, along with its dedicated kits, the BSC Blood Kit and BMSC Bone Marrow Kit. Continue Reading Korea’s FDA-cleared SMART M-CELL PRP Concentration System and S

WESTON, Fla., April 10, 2026 /PRNewswire/ - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States. This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access

DELRAY BEACH, Fla., April 10, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Penetration Testing as a Service (PTaaS) Market is projected to grow from USD 0.72 billion in 2026 to USD 1.98 billion by 2031 at a compound annual growth rate (CAGR) of 22.6% during the forecast period. Browse 362 market data Tables and 44 Figures spread through 303 Pages and in-depth TOC on "Penetration Testing as a Service (PTaaS) Market - Global Forecast to 2031" Penetration Testing as a Service (PTaaS)

AVAI, LCTX, OCGN, VRTX, and LGVN Advance Cell-Based and Gene-Therapy Approaches to Age-Related Disease Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Ocugen, Inc. (NASDAQ: OCGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Longeveron Inc. (NASDAQ: LGVN) Key Takeaways: Avaí Bio (OTCQB: AVAI) and its joint venture partner Austrianova announced on April 7, 2026, that they will prese

SAN FRANCISCO, April 10, 2026 /PRNewswire/ -- Pendulum Therapeutics, a biotechnology company pioneering microbiome science to transform human health, today announced an expanded clinical research collaboration with Mayo Clinic to explore new applications of microbiome-based interventions across women's health and dermatology. The expanded collaboration builds on a relationship that began in 2013 and reflects the organizations' shared commitment to advancing rigorous, evidence-based microbiome re

The agreement aims to expand access to the therapy in Brazil; The Technology is for patients who did not respond to conventional treatments. SHANGHAI and NANJING, China and PLEASANTON, Calif., April 10, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), today announced that it has signed a technology licensing agreement with the Instituto Butantan, a leading Brazilian public institution, for the local development of a CAR-T cell therapy for hematological cancer in Brazil. The technology uses

Public-private Council to guide the National Parkinson's Project, a whole-of-government federal initiative to accelerate research, treatments and cures for Parkinson's and related diseases. The Michael J. Fox Foundation played a central role in mobilizing grassroots effort that secured overwhelming bipartisan support for legislation authorizing the NPP. NEW YORK, April 10, 2026 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) today announced that its Chief Executiv

NEW YORK, April 10, 2026 /PRNewswire/ -- Jessica Shurer, Director of Clinical Affairs and Advocacy at CurePSP, has been appointed to the National Parkinson's Project (NPP) Advisory Council on Parkinson's Research, Care and Services — marking a critical step toward ensuring progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) are represented in the first-ever federal initiative to address Parkinson's disease and related conditions. Originally nam

Study assessing PharmaSens all-in-one insulin patch pump provides first evidence that combining glucose sensing and insulin administration in a single, wearable device is possible Next-generation niia device has potential to make diabetes management simpler, more effective and more affordable for insulin users BIEL/BIENNE, Switzerland, April 10, 2026 /PRNewswire/ -- PharmaSens AG, a Swiss developer of next-generation insulin patch pump systems, announced that the Journal of Diabetes Science and

16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) r